Aurora, Colo, August 27, 2019 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, announced today that
AURORA, Colo., Feb. 17, 2020 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on precision medicine cancer therapies, was featured in
– Machavert hits its preclinical proof of principle milestone that small molecule RAL GTPase inhibitors suppress KRAS mutant cancer metastasis
Aurora, Colo., Feb. 19, 2020. We held the Science Advisory Board (SAB) meeting to review our R&D progress and direction on
Aurora, Colo, March 28, 2019 /PRNewswire/ – Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision medicine cancer therapies, announced
Press Release: PR Newswire AURORA, Colo., Feb. 13, 2019 /PRNewswire/ — Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and
Press Release: PR Newswire AURORA, Colo., Jan. 4, 2019 /PRNewswire/ — Machavert Pharmaceuticals, a preclinical stage pharmaceutical company focused on immuno-oncology and precision
Press release (PR Newswire) Aurora, CO November 26, 2018 /PRNewswire/ – Machavert Pharmaceuticals, a drug development company focused on bioactive phospholipid therapeutics
Press Release: PR Newswire Aurora, CO – November 19, 2018 – /PRNewswire/ Machavert Pharmaceuticals received funding as part of the Colorado Office